B-ALL: combination therapy effectively controls high-risk subtypes
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
List view / Grid view
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
Using cortical organoids, researchers discovered that targeting KCNJ2 could reduce nerve cell death after TBI.
Single-cell RNA sequencing of ovaries resulted in the identification of four major cell types and four immune cell subtypes.
Organoid models enabled the researchers to study the effectiveness of eukaryotic ribosomal selective glycoside drugs on PKD cyst formation.
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets.
Researchers have presented new findings that offer potential pathways to arrest critical steps toward the accumulation of mutant tau.
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
One treatment with the anti-TRBC1-SG3249 ADC combination saw cancer elimination within seven days in mouse models.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
Transplant recipients of hematopoietic stem cells with a hereditary version of AD developed the disease at an accelerated rate.
The vaccine provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.
Researchers find how antibiotic treatments influence the microbiota, providing new strategies for preventing antibiotic-induced damage.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
Stem-cell based blastocyst models have enabled scientists to redefine the molecular signature and timing of the onset of gastrulation.